ArticleHealth science reports2025
Empiric Antibiotic Use With Rescue Infliximab Does Not Improve Outcomes in Acute Severe Ulcerative Colitis: A Retrospective Cohort Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut barrier-microbiota crosstalk in sepsis: from pathogenesis to potential therapies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Antibiotics are sometimes prescribed as concurrent therapy in the management of acute severe ulcerative colitis (ASUC) with a rationale of treating any presumed concurrent infections. It is unclear if there are data indicating any benefit of this clinical practice. We sought to evaluate the concurrent use of antibiotics with infliximab in patients hospitalized for the treatment of ASUC. Methods: We performed a retrospective cohort study on hospitalized patients with ASUC, comparing the outcomes of patients who received both rescue infliximab and antibiotics to patients who received rescue infliximab without antibiotics. The comparative cohorts were derived from the TriNetX US Collaborative Network. Propensity score matching was used to balance cohorts on baseline demographic and clinical characteristics. Kaplan Meier analyses and hazard ratios with 95% confidence intervals were calculated. Results: Concurrent administration of antibiotics and antimicrobials with rescue infliximab in ASUC does not result in any benefit in IBD related surgery (HR: 1.18; 95% CI: 0.82-1.70), colectomy (HR: 1.08; 95% CI: 0.54-2.13), sepsis (HR: 1.36; 95% CI: 0.84-2.20) and mortality (HR: 0.81; 95% CI: 0.32-2.05). Furthermore, the antibiotic cohort was more likely to utilize emergency department services (HR: 1.29; 95% CI: 1.02-1.64) and critical care services (HR: 2.36; 95% CI: 1.31-4.24) in the studied outcome time period. Conclusion: Empiric administration of antibiotics or antimicrobials with infliximab rescue therapy in ASUC does not improve outcomes and may be associated with higher health care utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.